HC Wainwright Has Optimistic Outlook of MeiraGTx Q4 Earnings

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Research analysts at HC Wainwright lifted their Q4 2027 earnings estimates for shares of MeiraGTx in a research report issued on Tuesday, May 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of $2.16 per share for the quarter, up from their previous estimate of $2.08. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.63) per share.

Several other equities research analysts also recently weighed in on MGTX. Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of MeiraGTx in a research report on Friday, March 27th. Wall Street Zen raised MeiraGTx from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a research report on Tuesday, April 21st. Piper Sandler upped their price target on MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, April 22nd. Finally, Bank of America upped their price target on MeiraGTx from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.83.

MeiraGTx Stock Performance

MGTX opened at $9.60 on Wednesday. The company has a 50-day moving average of $9.15 and a 200-day moving average of $8.30. The company has a market capitalization of $889.06 million, a P/E ratio of -6.49 and a beta of 1.23. MeiraGTx has a 1-year low of $5.02 and a 1-year high of $11.85.

MeiraGTx (NASDAQ:MGTX) last released its earnings results on Thursday, May 14th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04. The company had revenue of $0.29 million during the quarter, compared to the consensus estimate of $17.00 million. MeiraGTx had a negative net margin of 151.12% and a negative return on equity of 1,065.47%.

Hedge Funds Weigh In On MeiraGTx

Hedge funds and other institutional investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of MeiraGTx by 183.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 308,509 shares of the company’s stock valued at $2,453,000 after acquiring an additional 199,528 shares during the period. Jefferies Financial Group Inc. acquired a new position in shares of MeiraGTx during the fourth quarter valued at $2,371,000. ProShare Advisors LLC acquired a new position in shares of MeiraGTx during the fourth quarter valued at $94,000. Royce & Associates LP acquired a new position in shares of MeiraGTx during the fourth quarter valued at $1,400,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of MeiraGTx during the fourth quarter valued at $176,000. Institutional investors and hedge funds own 67.48% of the company’s stock.

Insiders Place Their Bets

In other MeiraGTx news, CFO Richard Giroux sold 56,000 shares of the firm’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $10.22, for a total value of $572,320.00. Following the transaction, the chief financial officer owned 971,530 shares of the company’s stock, valued at $9,929,036.60. This trade represents a 5.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,661 shares of the firm’s stock in a transaction dated Tuesday, April 7th. The stock was sold at an average price of $9.36, for a total transaction of $258,906.96. Following the completion of the transaction, the insider directly owned 668,505 shares in the company, valued at $6,257,206.80. This represents a 3.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 207,661 shares of company stock valued at $1,859,187 over the last quarter. Insiders own 7.50% of the company’s stock.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.